Cor Vasa 2022, 64(3):310-315 | DOI: 10.33678/cor.2022.026

(Immune Checkpoint Inhibitor Myocarditis: Current Views on Diagnosis and Treatment)

Barbora Chocholová, Petr Kuchynka, Tomáš Paleček

II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha

Immune checkpoint inhibitor (ICI) administration represents relatively new modality of cancer therapy that is increasingly used in the treatment of many malignancies, as its administration significantly improves survival of the patients. However, ICI administration may lead to several side effects, including cardiotoxic, with the most common and severe manifestation being the subject of this review, ICI-associated myocarditis. Although ICI-associated myocarditis has a low incidence, its mortality is high, reaching almost 50%. It is therefore important to be aware of the existence of ICI-associated myocarditis, its clinical manifestations, timely diagnosis, and early administration of immunosuppressive treatment with high-dose corticoids representing the first-line therapy.

Keywords: AV block, Cardiotoxicity, Immune checkpoint inhibitors, Immunosuppressive therapy, Myocarditis

Received: February 8, 2022; Revised: March 6, 2022; Accepted: March 16, 2022; Published: June 22, 2022  Show citation